DMPA: battered and bruised but still needed and used in the USA

References

• Lande RE. New era for injectables. Population Reports, Series K, No. 5. Population Information Program, Johns Hopkins School of Public Health, Baltimore, MD, USA, 31 (1995).
   Google Scholar
• Rosenfield A, Maine D, Rochat R, Shelton J, Hatcher RA. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues? JAMA249(21), 2922–2928 (1983).
   PubMed Web of Science ®Google Scholar
• Ouatas T, Halverson D, Steeg PS. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin. Cancer Res.9(10 Pt 1), 3763–3772 (2003).
   PubMed Web of Science ®Google Scholar
• Strom BL, Berlin JA, Weber AL et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception69(5), 353–360 (2004).
   PubMed Web of Science ®Google Scholar
• Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA273(10), 799–804 (1995).
   PubMed Web of Science ®Google Scholar
• Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet338(8771), 833–838 (1991).
   PubMed Web of Science ®Google Scholar
• Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int. J. Cancer49(2), 191–195 (1991).
   PubMed Web of Science ®Google Scholar
• Shapiro S, Rosenberg L, Hoffman M et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control14(5), 485–495 (2003).
   PubMed Web of Science ®Google Scholar
• Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int. J. Cancer49(2), 186–190 (1991).
   PubMed Web of Science ®Google Scholar
• Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982–2002. Adv. Data350, 1–36 (2004).
   Google Scholar
• Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet. Gynecol.96(3), 431–439 (2000).
   PubMed Web of Science ®Google Scholar
• Morrison CS, Bright P, Wong EL et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex. Transm. Dis.31(9), 561–567 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Peralta L, Farmer M, Graham NM, Gaydos C, Zenilman J. Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. Sex. Transm. Dis.27(6), 313–319 (2000).
   PubMed Web of Science ®Google Scholar
• Stringer EM, Levy J, Sinkala M et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS23, 1377–1382 (2009).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception80(1), 7–17 (2009).
   PubMed Web of Science ®Google Scholar
• Boonstra H, Duran V, Northington Gamble V, Blumenthal P, Dominguez L, Pies C. The ‘boom and bust phenomenon’: the hopes, dreams, and broken promises of the contraceptive revolution. Contraception61(1), 9–25 (2000).
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 415: depot medroxyprogesterone acetate and bone effects. Obstet. Gynecol.112(3), 727–730 (2008).
   PubMedGoogle Scholar
• WHO. WHO Statement on hormonal contraception and bone health. Wkly Epidemiol. Rec.80, 297–304 (2005).
   PubMedGoogle Scholar
• Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. National Center for Health Statistics. Vital Health Stat.23 (2010).
   Google Scholar
• Petta CA, Faúndes A, Dunson TR et al. Timing of onset of contraceptive effectiveness in Depo-Provera users. Part II. Effects on ovarian function. Fertil. Steril.70(5), 817–820 (1998).
   PubMed Web of Science ®Google Scholar
• Petta CA, Faúndes A, Dunson TR et al. Timing of onset of contraceptive effectiveness in Depo-Provera users: part I. Changes in cervical mucus. Fertil. Steril.69(2), 252–257 (1998).
   PubMed Web of Science ®Google Scholar
• Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception65(1), 21–27 (2002).
   PubMed Web of Science ®Google Scholar
• Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J. Reprod. Med.41(5 Suppl.), 381–390 (1996).
   PubMed Web of Science ®Google Scholar
• Jain J, Dutton C, Nicosia A, Wajszczuk C, Bode FR, Mishell DR Jr. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception70(1), 11–18 (2004).
   PubMed Web of Science ®Google Scholar
• Mimura N, Kobayashi K, Nakamura Y, Shimada N, Hosokawa M, Chiba K. Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo.Life Sci.73(25), 3201–3212 (2003).
   PubMed Web of Science ®Google Scholar
• Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil. Steril.90(4), 965–971 (2008).
   PubMed Web of Science ®Google Scholar
• Schwallie PC, Assenzo JR. Contraceptive use – efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil. Steril.24(5), 331–339 (1973).
   PubMed Web of Science ®Google Scholar
• Trussell J, Kost K. Contraceptive failure in the United States: a critical review of the literature. Stud. Fam. Plann.18(5), 237–283 (1987).
   PubMed Web of Science ®Google Scholar
• Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS. Pregnancies diagnosed during Depo-Provera use. Contraception66(3), 169–172 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg AB, Grimes DA. Injectable contraceptives. In: Contraceptive Technology (19th Edition). Hatcher RA, Trussell J, Nelson AL et al. (Eds). 168, 61. Ardent Media Inc., NY, USA (2008).
   Google Scholar
• Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception70(4), 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception77(1), 10–21 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson AL, Westhoff C, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation. Obstet. Gynecol.112(4), 782–787 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson AL, Katz T. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA. Contraception75(2), 84–87 (2007).
   PubMed Web of Science ®Google Scholar
• Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception80(4), 337–345 (2009).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Cushman M, Badger GJ, Johnson JV. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil. Steril.87, 1267–1270 (2007).
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins – Gynecology. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet. Gynecol.107(6), 1453–1472 (2006).
   PubMedGoogle Scholar
• Virutamasen P, Leepipatpaiboon S, Kriengsinyot R et al. Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants. Contraception54, 153–157 (1996).
   PubMed Web of Science ®Google Scholar
• Pardthaisong T, Yenchit C, Gray R. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception45, 313–324 (1992).
   PubMed Web of Science ®Google Scholar
• Halderman LD, Nelson AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am. J. Obstet. Gynecol.186, 1250–1256; discussion 1256–1258 (2002).
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology34(9), 1255–1258 (1984).
   PubMed Web of Science ®Google Scholar
• de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception56(5), 313–316 (1997).
   PubMed Web of Science ®Google Scholar
• Choksuchat C, Zhao S, Deutch TD, Kimble TD, Archer DF. Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells. Contraception79(2), 139–145 (2009).
   PubMed Web of Science ®Google Scholar
• Arowojolu AO. Treatment of endometriosis with depot medroxyprogesterone acetate: a preliminary experience. Afr. J. Med. Med. Sci.29(1), 55–58 (2000).
   PubMedGoogle Scholar
• Walch K, Unfried G, Huber J et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis – a pilot study. Contraception79, 29–34 (2009).
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum. Reprod.21(1), 248–256 (2006).
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil. Steril.85(2), 314–325 (2006).
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am. J. Obstet. Gynecol.175(2), 396–401 (1996).
   PubMed Web of Science ®Google Scholar
• Tokushige N, Markham R, Russell P, Fraser IS. Effect of progestogens and combined oral contraceptives on nerve fibers in peritoneal endometriosis. Fertil. Steril.92(4), 1234–1239 (2009).
   PubMed Web of Science ®Google Scholar
• Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case–control study. Br. J. Obstet. Gynaecol.103, 909–914 (1996).
   PubMedGoogle Scholar
• American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion no. 448: menstrual manipulation for adolescents with disabilities. Obstet. Gynecol.114, 1428–1431 (2009).
   PubMedGoogle Scholar
• Potter LS, Dalberth BT, Cañamar R, Betz M. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department. Contraception56(5), 305–312 (1997).
   PubMed Web of Science ®Google Scholar
• Sangi-Haghpeykar H, Poindexter AN 3rd, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet. Gynecol.88, 227–233 (1996).
   PubMed Web of Science ®Google Scholar
• Polaneczky M, Liblanc M. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J. Adolesc. Health23(2), 81–88 (1998).
   PubMed Web of Science ®Google Scholar
• Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception76(4), 267–272 (2007).
   PubMed Web of Science ®Google Scholar
• Paul C, Skegg DC, Williams S. Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation. Contraception56(4), 209–214 (1997).
   PubMed Web of Science ®Google Scholar
• Jones RK, Darroch JE, Henshaw SK. Contraceptive use among U.S. women having abortions in 2000–2001. Perspect. Sex. Reprod. Health34, 294–303 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson AR, Kalmuss D, Cushman LF, Romero D, Heartwell S, Rulin M. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women. Am. J. Public Health87, 1532–1534 (1997).
   PubMed Web of Science ®Google Scholar
• Bajos N, Lamarche-Vadel A, Gilbert F et al. Contraception at the time of abortion: high-risk time or high-risk women? Hum. Reprod.21(11), 2862–2867 (2006).
   PubMed Web of Science ®Google Scholar
• Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception80(2), 113–118 (2009).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Odom SD, Breitkopf CR, Rahman M. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 µg oral contraceptive pills. Am. J. Obstet. Gynecol.199(4), 351.e1–12 (2008).
   Web of Science ®Google Scholar
• Morrison LA, Larkspur L, Calibuso MJ, Brown S. Women’s attitudes about menstruation and associated health and behavioral characteristics. Am. J. Health Behav.34(1), 90–100 (2010).
   PubMed Web of Science ®Google Scholar
• Edelman A, Lew R, Cwiak C, Nichols M, Jensen J. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception75(6), 450–453 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrero S, Abbamonte LH, Giordano M et al. What is the desired menstrual frequency of women without menstruation-related symptoms? Contraception73(5), 537–541 (2006).
   PubMed Web of Science ®Google Scholar
• Clark LR, Barnes-Harper KT, Ginsburg KR, Holmes WC, Schwarz DF. Menstrual irregularity from hormonal contraception: a cause of reproductive health concerns in minority adolescent young women. Contraception74(3), 214–219 (2006).
   PubMed Web of Science ®Google Scholar
• Gold MA, Coupey SM. Young women’s attitudes toward injectable and implantable contraceptives. J. Pediatr. Adolesc. Gynecol.11, 17–24 (1998).
   PubMedGoogle Scholar
• Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception74(3), 234–238 (2006).
   PubMed Web of Science ®Google Scholar
• Gray RH, Parker RA, Diethelm P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Br. J. Obstet. Gynaecol.88(3), 317–321 (1981).
   PubMedGoogle Scholar
• Danli S, Qingxiang S, Guowei S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception62(1), 15–18 (2000).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Smith RD, Blair JM, Dwyer J, Brown RT. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics94(5), 687–694 (1994).
   PubMed Web of Science ®Google Scholar
• Sereepapong W, Chotnopparatpattara P, Taneepanichskul S, Markham R, Russell P, Fraser IS. Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users. Hum. Reprod.19(3), 547–552 (2004).
   PubMed Web of Science ®Google Scholar
• Thurman AR, Soper DE. Endometrial histology of depomedroxyprogesterone acetate users: a pilot study. Infect. Dis. Obstet. Gynecol.2006, 69402 (2006).
   PubMedGoogle Scholar
• Hussein M. Transvaginal Doppler sonography for evaluation of irregular uterine bleeding with DMPA. Arch. Gynecol. Obstet. DOI: 10.1007/s00404-010-1569-z (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Dempsey A, Roca C, Westhoff C. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. Contraception82(3), 250–255 (2010).
   PubMed Web of Science ®Google Scholar
• Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J. Adolesc. Health16(5), 379–384 (1995).
   PubMed Web of Science ®Google Scholar
• Said S, Sadek W, Rocca M et al. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Hum. Reprod.11(Suppl. 2), 1–13 (1996).
   PubMedGoogle Scholar
• Abdel-Aleem H, d’Arcangues C, Vogelsong KK, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst. Rev.4, CD003449 (2007).
   Google Scholar
• Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception70(4), 277–279 (2004).
   PubMed Web of Science ®Google Scholar
• Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception73(6), 584–587 (2006).
   PubMed Web of Science ®Google Scholar
• Li A, Felix JC, Yang W, Xiong DW, Minoo P, Jain JK. Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. Contraception76(1), 57–65 (2007).
   PubMed Web of Science ®Google Scholar
• Morison NB, Kaitu’u-Lino TJ, Fraser IS, Salamonsen LA. Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives. Reproduction136, 267–274 (2008).
   PubMed Web of Science ®Google Scholar
• Sadeghi-Bazargani H, Ehdaeivand F, Arshi S, Eftekhar H, Sezavar H, Amanati L. Low-dose oral contraceptive to re-induce menstrual bleeding in amenorrheic women on DMPA treatment: a randomized clinical trial. Med. Sci. Monit.12(10), CR420–CR425 (2006).
   PubMed Web of Science ®Google Scholar
• Lei ZW, Wu SC, Garceau RJ et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception53(6), 357–361 (1996).
   PubMed Web of Science ®Google Scholar
• Chumnijarakij T, Sunyavivat S, Onthuam Y, Udomprasertgul V. Study on the factors associated with contraceptive discontinuations in Bangkok. Contraception29(3), 241–249 (1994).
   Google Scholar
• Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception63(3), 143–146 (2001).
   PubMed Web of Science ®Google Scholar
• Risser WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J. Adolesc. Health24(6), 433–436 (1999).
   PubMed Web of Science ®Google Scholar
• Hubacher D, Goco N, Gonzalez B, Taylor D. Factors affecting continuation rates of DMPA. Contraception60, 345–351 (1999).
   PubMed Web of Science ®Google Scholar
• Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am. J. Clin. Nutr.73(1), 19–26 (2001).
   PubMed Web of Science ®Google Scholar
• Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception52(4), 215–219 (1995).
   PubMed Web of Science ®Google Scholar
• Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception58(3), 149–151 (1998).
   Web of Science ®Google Scholar
• Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet. Gynecol.114(2 Pt 1), 279–284 (2009).
   PubMed Web of Science ®Google Scholar
• Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception22, 605–622 (1980).
   PubMed Web of Science ®Google Scholar
• Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J. Pediatr. Adolesc. Gynecol.15(2), 79–82 (2002).
   PubMedGoogle Scholar
• Bonny AE, Britto MT, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J. Pediatr. Adolesc. Gynecol.17(2), 109–115 (2004).
   PubMedGoogle Scholar
• Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch. Pediatr. Adolesc. Med.160, 40–45 (2006).
   PubMed Web of Science ®Google Scholar
• Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception80(4), 346–354 (2009).
   PubMed Web of Science ®Google Scholar
• Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, Fernandes AM. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception81(2), 107–111 (2010).
   PubMed Web of Science ®Google Scholar
• Wellings K, Zhihong Z, Krentel A, Barrett G, Glasier A. Attitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception76(3), 208–214 (2007).
   PubMed Web of Science ®Google Scholar
• Civic D, Scholes D, Ichikawa L et al. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception61(6), 385–390 (2000).
   PubMed Web of Science ®Google Scholar
• Ott MA, Shew ML, Ofner S, Tu W, Fortenberry JD. The influence of hormonal contraception on mood and sexual interest among adolescents. Arch. Sex. Behav.37(4), 605–613 (2008).
   PubMed Web of Science ®Google Scholar
• Westhoff C, Wieland D, Tiezzi L. Depression in users of depo-medroxyprogesterone acetate. Contraception51(6), 351–354 (1995).
   PubMed Web of Science ®Google Scholar
• Westhoff C, Truman C, Kalmuss D et al. Depressive symptoms and Depo-Provera. Contraception57(4), 237–240 (1998).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet. Gynecol.92(4 Pt 1), 569–573 (1998).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet. Gynecol.98(4), 576–582 (2001).
   PubMed Web of Science ®Google Scholar
• Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet. Gynecol.95(5), 736–744 (2000).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Stager M, Bonny A et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J. Adolesc. Health35(6), 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil. Steril.82(6), 1580–1586 (2004).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet. Gynecol.103(5 Pt 1), 899–906 (2004).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Bonny AE, Stager M et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil. Steril.90(6), 2060–2067 (2008).
   PubMed Web of Science ®Google Scholar
• Harel Z, Wolter K, Gold M et al. The impact of depot medroxyprogesterone acetate on adolescents’ bone mineral density: adolescents who lose 5% or more from baseline versus those who lose less than 5%. Presented at: Annual Meeting of the North American Society for Pediatric and Adolescent Gynecology. Champions Gate, FL, USA, 18–20 May 2006.
   Google Scholar
• Rahman M, Berenson AB. Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate. Obstet. Gynecol.115(1), 35–40 (2010).
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil. Steril.86(5), 1466–1474 (2006).
   PubMed Web of Science ®Google Scholar
• Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM; Society for Adolescent Medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents – the black box warning: a position paper of the Society for Adolescent Medicine. J. Adolesc. Health39(2), 296–301 (2006).
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet. Gynecol.105(5 Pt 1), 1114–1118 (2005).
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am. J. Obstet. Gynecol.186(5), 978–983 (2002).
   PubMed Web of Science ®Google Scholar
• Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos. Int.12(1), 35–42 (2001).
   PubMed Web of Science ®Google Scholar
• Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues16(6), 346–352 (2006).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception74(2), 90–99 (2006).
   PubMed Web of Science ®Google Scholar
• Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch. Pediatr. Adolesc. Med.159(2), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Zhang Y, Constant D et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception76(6), 425–431 (2007).
   PubMed Web of Science ®Google Scholar
• Harel Z, Johnson CC, Gold MA et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception81(4), 281–291 (2010).
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception77(2), 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Sowers M, Corton G, Shapiro B et al. Changes in bone density with lactation. JAMA269(24), 3130–3135 (1993).
   PubMed Web of Science ®Google Scholar
• Karlsson MK, Ahlborg HG, Karlsson C. Maternity and bone mineral density. Acta Orthop.76(1), 2–13 (2005).
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst. Rev.4, CD006033 (2009).
   Google Scholar
• Beksinska ME, Kleinschmidt I, Smit JA, Farley TM, Rees HV. Bone mineral density in young women aged 19–24 after 4–5 years of exclusive and mixed use of hormonal contraception. Contraception80(2), 128–132 (2009).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Rahman M, Breitkopf CR, Bi LX. Effects of depotmedroxyprogesterone acetate and 20-microgram oral contraceptives on bone mineral density. Obstet. Gynecol.112, 788–799 (2008).
   PubMed Web of Science ®Google Scholar
• Marx PA, Spira AI, Gettie A et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med.2(10), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Trevisan M, Andrade L et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception62(1), 23–27 (2000).
   PubMed Web of Science ®Google Scholar
• Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int. J. Epidemiol.36, 166–174 (2007).
   PubMed Web of Science ®Google Scholar
• Kleinschmidt I, Rees H, Delany S et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception75(6), 461–467 (2007).
   PubMed Web of Science ®Google Scholar
• Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract. Res. Clin. Obstet. Gynaecol.23(2), 263–284 (2009).
   PubMed Web of Science ®Google Scholar
• Bulterys M, Chao A, Habimana P, Dushimimana A, Nawrocki P, Saah A. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS8(11), 1585–1591 (1994).
   PubMed Web of Science ®Google Scholar
• Morrison CS, Richardson BA, Mmiro F et al; Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormonal contraception and the risk of HIV acquisition. AIDS21(1), 85–95 (2007).
   PubMed Web of Science ®Google Scholar
• Baeten JM, Benki S, Chohan V et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS21, 1771–1777 (2007).
   PubMed Web of Science ®Google Scholar
• Martin HL Jr, Nyange PM, Richardson BA et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J. Infect. Dis.178(4), 1053–1059 (1998).
   PubMed Web of Science ®Google Scholar
• Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil. Steril.90(4), 965–971 (2008).
   PubMed Web of Science ®Google Scholar
• Watts DH, Park JG, Cohn SE et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception77(2), 84–90 (2008).
   PubMed Web of Science ®Google Scholar
• Pettifor A, Delany S, Kleinschmidt I, Miller WC, Atashili J, Rees H. Use of injectable progestin contraception and risk of STI among South African women. Contraception80(6), 555–560 (2009).
   PubMed Web of Science ®Google Scholar
• Morrison CS, Bright P, Wong EL et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex. Transm. Dis.31(9), 561–567 (2004).
   PubMed Web of Science ®Google Scholar
• Baeten JM, Nyange PM, Richardson BA et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am. J. Obstet. Gynecol.185, 380–385 (2001).
   PubMed Web of Science ®Google Scholar
• Gray RH. Reduced risk of pelvic inflammatory disease with injectable contraceptives. Lancet1(8436), 1046 (1985).
   PubMedGoogle Scholar
• Sneed R, Westhoff C, Morroni C, Tiezzi L. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection. Contraception71(2), 99–103 (2005).
   PubMed Web of Science ®Google Scholar
• Rickert VI, Tiezzi L, Lipshutz J, León J, Vaughan RD, Westhoff C. Depo Now: preventing unintended pregnancies among adolescents and young adults. J. Adolesc. Health40, 22–28 (2007).
   PubMed Web of Science ®Google Scholar
• Balkus J, Miller L. Same-day administration of depot-medroxyprogesterone acetate injection: a retrospective chart review. Contraception71(5), 395–398 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg AB, Cardenas LH, Hubbard AE, Darney PD. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol. Contraception66(4), 215–220 (2002).
   PubMed Web of Science ®Google Scholar
• Steiner MJ, Kwok C, Stanback J et al. Injectable contraception: what should the longest interval be for reinjections? Contraception77(6), 410–414 (2008).
   PubMed Web of Science ®Google Scholar
• Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables – depot medroxyprogesterone acetate or norethisterone enantate? Contraception80(4), 391–408 (2009).
   PubMed Web of Science ®Google Scholar
• Picardo C. Pharmacist-administered depot medroxyprogesterone acetate. Contraception73(6), 559–561 (2006).
   PubMed Web of Science ®Google Scholar
• Lakha F, Henderson C, Glasier A. The acceptability of self-administration of subcutaneous Depo-Provera. Contraception72(1), 14–18 (2005).
   PubMed Web of Science ®Google Scholar
• Prabhakaran S. Self-administration of injectable contraceptives. Contraception77, 315–317 (2008).
   PubMed Web of Science ®Google Scholar
• Selo-Ojeme DO, Tillisi A, Welch CC. Anaphylaxis from medroxyprogesterone acetate. Obstet. Gynecol.103(5 Pt 2), 1045–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Brooks GG. Anaphylactoid shock with medroxyprogesterone acetate: a case report. J. LA State Med. Soc.126, 397–399 (1974).
   PubMedGoogle Scholar